Sign up
Log in
News
RDY
81.22
+0.47%
0.38
Dr. Reddy’s Sells Stake to Nestlé India
TipRanks · 2d ago
Dr Reddys Labs: Report of foreign issuer
Press release · 3d ago
Dr. Reddy’s Considers Stock Split Proposal
TipRanks · 3d ago
Weekly Report: what happened at RDY last week (0715-0719)?
Weekly Report · 4d ago
Dr. Reddy’s Unveils VONO™ for India Market
TipRanks · 07/18 18:17
Dr. Reddy’s Confronts GST Demand Order
TipRanks · 07/15 10:51
Weekly Report: what happened at RDY last week (0708-0712)?
Weekly Report · 07/15 09:05
U.S. Senate passes bill to trim Big Pharma "patent thickets"
U.S. Senate passes bill to trim Big Pharma "patent thickets" to hinder generic competition. The bill is intended to ease the entrance of biosimilars and other generic drugs onto the market. The Affordable Prescriptions for Patients Act moves next to the U.s. House for consideration.
Seeking Alpha · 07/12 16:35
Dr. Reddy’s Q1FY25 Financial Results Imminent
TipRanks · 07/10 15:27
Weekly Report: what happened at RDY last week (0701-0705)?
Weekly Report · 07/08 09:05
Dr. Reddy’s Announces 40th AGM and E-voting Details
TipRanks · 07/05 11:02
Weekly Report: what happened at RDY last week (0624-0628)?
Weekly Report · 07/01 09:05
Dr. Reddy’s and Zydus Partner for Cancer Drug Access
TipRanks · 06/28 14:30
Dr. Reddy's Laboratories Reaches Analyst Target Price
NASDAQ · 06/28 11:44
India plans incentives for diabetes, obesity drug makers in 2026, government official says
India plans incentives for diabetes, obesity drug makers in 2026, government official says. GLP-1 drugs are used to treat diabetes and obesity. Drugmakers across the globe are looking to grab a slice of the weight-loss drugs market. India has high obesity rates, and has the world's second-highest diabetes population.
Reuters · 06/28 10:42
Dr. Reddy’s Releases Investor Call Recording
TipRanks · 06/28 10:30
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
NASDAQ · 06/27 14:25
Deals of the day-Mergers and acquisitions
UltraTech Cement will buy a 23% stake in rival India Cements for up to $226 million. France's Saint-Gobain agrees to buy Dubai-based construction chemicals company FOSROC. Nokia agrees to sell its submarine business ASN to the French state for $374 million.
Reuters · 06/27 09:51
INDIA STOCKS-UltraTech Cement, Reliance power Indian shares to record highs
UltraTech Cement, Reliance power Indian shares to record highs. Ultratech Cement jumps after announcing a stake purchase in rival India Cements. The NSE Nifty 50 and S&P BSE Sensex hit record highs on Thursday. Indian equity benchmarks scaled record closing highs in the last two sessions.
Reuters · 06/27 05:04
BUZZ-India's Dr Reddy's up as unit to acquire Haleon's nicotine replacement therapy
India's Dr Reddy's Laboratories up 2.3% as unit to acquire Haleon's replacement therapy business. Stock top gainer on Nifty pharma index which is up 0.2%. Generic drugmaker said it will acquire UK-based Hale on's HLN.L for 500 million pounds.
Reuters · 06/27 05:03
More
Webull provides a variety of real-time RDY stock news. You can receive the latest news about Dr Reddys Labs through multiple platforms. This information may help you make smarter investment decisions.
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.